Whether Medicare pays for a GLP-1 drug like Wegovy, Zepbound, Ozempic, or Mounjaro depends on why it is prescribed. Medicare Part D is barred by law from covering a drug used solely to lose weight, but it does cover GLP-1s prescribed for certain medical conditions, and a new time-limited program now offers separate access for weight reduction. This guide walks through each scenario, what you would pay, and what to do if your plan says no.
In This Guide
- Does Medicare cover weight-loss drugs? The rule that decides coverage
- When Part D covers a GLP-1: the medical indications
- What a covered GLP-1 costs under Part D
- How Medicare covers weight-loss drugs, by scenario
- The Medicare GLP-1 Bridge
- What if your plan denies or restricts the drug?
- Frequently asked questions
- Learn More
Does Medicare cover weight-loss drugs? The rule that decides coverage
The starting point is a statutory one. Medicare Part D is prohibited by law from covering a drug when it is used solely for weight loss, meaning to reduce excess body weight or to maintain weight reduction. That prohibition applies to GLP-1 drugs the same way it applies to any other agent used for weight loss alone.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
The same drug, however, can be covered when it treats a recognized medical condition. Coverage turns on the reason on the prescription, not on the brand: the same molecule (semaglutide) is barred as Wegovy prescribed for weight loss yet covered as Ozempic prescribed for diabetes. A GLP-1 prescribed for a use that Part D can cover is handled under your Part D drug plan, subject to the plan's formulary, prior-authorization rules, and cost-sharing.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
When Part D covers a GLP-1: the medical indications
A GLP-1 prescribed for a Part-D-coverable medical use is covered by your Part D plan, the same as any other covered drug. Coverable uses include the following.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
- Type 2 diabetes. A GLP-1 prescribed to treat Type 2 diabetes is covered under your Part D diabetes coverage, subject to your plan's rules.
- Obstructive sleep apnea (OSA). For example, Zepbound for moderate-to-severe OSA in adults who have obesity.
- Reducing the risk of major adverse cardiovascular events. For example, Wegovy in adults with established cardiovascular disease who also have obesity or overweight. This is the first time a primarily weight-management molecule reached Part D coverage through a non-weight-loss indication, and many readers do not know it is possible.
- Noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis).
In each of these cases, you get the drug through your Part D plan, and normal plan formularies, prior authorization, and cost-sharing apply. A GLP-1 prescribed for one of these indications goes through regular Part D, not the Bridge described below.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
What a covered GLP-1 costs under Part D
When a GLP-1 is covered for a medical indication, it costs whatever your plan charges for a drug on its formulary, not the Bridge's flat copay. Two mechanics decide the number: your plan's rules for the drug, and the standard Part D benefit math.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
- Formulary and access rules. Plans place each covered GLP-1 on a cost tier and often attach prior authorization, step therapy, or quantity limits, so your prescriber may need to document the diagnosis before the plan pays. These rules vary by plan.
- The benefit phases. Each plan sets its own deductible, up to a federal maximum of $615 in 2026. After the deductible, you pay 25% coinsurance on covered drugs until your out-of-pocket spending reaches the annual cap of $2,100 for 2026, after which you pay $0 for covered Part D drugs for the rest of the year.Centers for Medicare & Medicaid Services. (n.d.). How much does Medicare drug coverage cost?. medicare.gov. Retrieved Jun 24, 2026, from https://www.medicare.gov/health-drug-plans/part-d/basics/costs,Centers for Medicare & Medicaid Services. (2026). Final CY 2026 Part D Redesign Program Instructions - CMS. cms.gov. Retrieved Jul 10, 2026, from https://www.cms.gov/files/document/final-cy-2026-part-d-redesign-program-instruction.pdf
Because a month of a brand-name GLP-1 can be expensive, many enrollees whose drug is covered reach that $2,100 cap partway through the year and then pay nothing more.Centers for Medicare & Medicaid Services. (2026). Final CY 2026 Part D Redesign Program Instructions - CMS. cms.gov. Retrieved Jul 10, 2026, from https://www.cms.gov/files/document/final-cy-2026-part-d-redesign-program-instruction.pdf If you get your drug coverage through a Medicare Advantage plan with Part D (an MA-PD plan), the same federal cap applies, though the plan sets its own tiers and cost-sharing.
How Medicare covers weight-loss drugs, by scenario
The table below distinguishes the common scenarios. The pathway, and the cost, depends on the reason the drug is prescribed.
| Reason the GLP-1 is prescribed | How Medicare handles it |
|---|---|
| Weight loss only | Not covered under regular Part D. May be available through the Medicare GLP-1 Bridge at $50 per monthly supply (temporary; July 1, 2026 to Dec. 31, 2027) |
| Type 2 diabetes | Covered under regular Part D, subject to plan rules and cost-sharing |
| Cardiovascular risk, with established CV disease plus obesity or overweight | Covered under regular Part D (for example, Wegovy) |
| Obstructive sleep apnea, with obesity | Covered under regular Part D (for example, Zepbound) |
| Noncirrhotic MASH | Covered under regular Part D |
The Medicare GLP-1 Bridge
For the weight-reduction use that Part D otherwise excludes, CMS has created the Medicare GLP-1 Bridge, a time-limited demonstration. It gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight reduction between July 1, 2026 and December 31, 2027.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
The key terms are these.
- Cost. The copay is $50 for a monthly supply.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
- No deductible. The drugs are furnished outside the Part D benefit payment flow, so the Part D deductible does not apply and the cost does not count toward your Part D phases.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
- No sign-up. Beneficiaries do not need to register or opt in.
- It is temporary. The demonstration ends December 31, 2027.
The Bridge covers eligible Medicare Part D beneficiaries. Because both standalone Part D drug plans and Medicare Advantage plans that include Part D (MA-PD plans) provide Part D coverage, MA-PD enrollees are included on the same terms, with no separate registration; confirm your own eligibility with your plan.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
The drugs included in the Bridge for weight reduction are Foundayo, Wegovy (injection and tablets), and Zepbound (the KwikPen formulation only). The single-dose vial and single-dose pen formulations of Zepbound are not included. The drug list was last updated April 6, 2026.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
This is a fast-moving area of policy, and the Bridge is a temporary demonstration scheduled to end after December 31, 2027. Confirm the current status, your eligibility, and which formulations are included with Medicare or your Part D plan before you rely on it. For broader context on coverage limits, see what Medicare doesn't cover.Centers for Medicare & Medicaid Services. (n.d.). Medicare GLP-1 Bridge: Information for Medicare Beneficiaries - CMS. medicare.gov. Retrieved Jul 12, 2026, from https://www.medicare.gov/coverage/weight-loss-drugs
What if your plan denies or restricts the drug?
If your Part D plan requires prior authorization for a covered GLP-1, or denies it, you have a defined path. Part D drug decisions follow a five-level appeals process that begins with your own plan, and plans must offer a faster track when your health cannot wait.Centers for Medicare & Medicaid Services. (n.d.). Appeals in Original Medicare. medicare.gov. Retrieved Jun 24, 2026, from https://www.medicare.gov/providers-services/claims-appeals-complaints/appeals/original-medicare The steps below apply whether your drug is covered for a medical indication or you are pursuing a Bridge drug.
Check your plan's formulary first
Use the Medicare Plan Finder at medicare.gov or call your plan to confirm whether your GLP-1 is on the formulary and what prior-authorization, step-therapy, or quantity rules apply.
Ask your prescriber to document the indication
If prior authorization is required, your doctor submits the diagnosis and clinical justification (for example, Type 2 diabetes or established cardiovascular disease). This is often what turns a denial into an approval.
Request a coverage determination
Ask the plan in writing for a coverage determination or an exception (for a non-formulary drug or to waive a restriction). The plan must respond, and you can request an expedited decision (generally within 72 hours) if waiting could seriously harm your health.
Appeal a denial
If the plan says no, appeal: Level 1 is a redetermination by the plan, Level 2 is review by an Independent Review Entity, and further levels go to an Administrative Law Judge, the Medicare Appeals Council, and federal court. See how Medicare appeals work for the full process and deadlines.
Frequently Asked Questions
Does Medicare cover Ozempic or Wegovy for weight loss?
Not under regular Part D. By law, Part D cannot cover a drug used solely for weight loss. A GLP-1 such as Wegovy can be covered under Part D when it is prescribed for a covered medical condition, for example reducing cardiovascular risk in adults with established cardiovascular disease who also have obesity or overweight. Separately, the Medicare GLP-1 Bridge offers Wegovy for weight reduction at $50 a month through December 31, 2027.
What is the Medicare GLP-1 Bridge and how much does it cost?
The Medicare GLP-1 Bridge is a time-limited CMS demonstration that gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs for weight reduction from July 1, 2026 through December 31, 2027. The copay is $50 for a monthly supply. Because the drugs are furnished outside the Part D benefit payment flow, the Part D deductible does not apply. You do not need to register or opt in.
Will Medicare cover a GLP-1 for my diabetes?
Yes, subject to your plan's rules. A GLP-1 prescribed to treat Type 2 diabetes is a Part-D-coverable use, so your Part D plan covers it under its formulary, prior-authorization, and cost-sharing rules. This is regular Part D coverage, not the Bridge.
Which GLP-1 drugs are in the Bridge program?
For weight reduction, the Bridge includes Foundayo, Wegovy (injection and tablets), and Zepbound in the KwikPen formulation only. The single-dose vial and single-dose pen formulations of Zepbound are not included. The drug list was last updated April 6, 2026, so confirm the current list with Medicare or your plan.
How do I find out whether my Part D plan covers a specific GLP-1?
Check your plan's formulary using the Medicare Plan Finder at medicare.gov, or call your plan or 1-800-MEDICARE (1-800-633-4227). The formulary shows whether the drug is covered, its cost tier, and any prior-authorization, step-therapy, or quantity limits. Coverage and cost can differ from one plan to another, so verify against your own plan.
What can I do if my plan denies the GLP-1?
Ask the plan for a coverage determination or exception, and have your prescriber document the medical indication. If the plan still denies it, you can appeal through Part D's five levels, starting with a redetermination by the plan and then review by an Independent Review Entity. You can request an expedited (fast) decision, generally within 72 hours, when your health cannot wait.
Learn More
Find personalized help understanding your Medicare GLP-1 coverage at brevy.com.
The information on Brevy.com is for educational purposes only and is not a substitute for professional legal, financial, or medical advice. Rules vary by state and program and change frequently. Always verify with the relevant agency or a qualified professional. Brevy is not a law firm, financial advisor, or healthcare provider.